Sensus Healthcare Partners with MIS Healthcare to Distribute SRT Systems in the United Kingdom and Ireland
Full line of Sensus’ SRT products for the non-invasive treatment of non-melanoma skin cancer and keloids now available to MIS Healthcare customers
BOCA RATON, Fla, July 06, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a partnership with MIS Healthcare to distribute Sensus’ superficial radiation therapy (SRT) products in the United Kingdom and Ireland. This agreement includes the company’s SRT-100™, SRT-100+™ and SRT-100 Vision™ systems for the treatment of non-melanoma skin cancer and keloids.
“Our new partnership with MIS Healthcare provides Sensus with greater exposure in the United Kingdom and Ireland, and opens new markets for our SRT products. Having received the CE mark for our SRT system in 2011, we look forward to this new opportunity with a highly capable partner and a shared commitment to the highest level of customer service,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.
Each day nearly 600 people are diagnosed with non-melanoma skin cancer in the United Kingdom and Ireland. The SRT family of products offers them a new treatment option that is non-invasive and painless. In addition, unlike Mohs surgery, with SRT there is no post-procedure downtime for recovery and healing.
“The Sensus team looks forward to working with MIS Healthcare to expand the reach of our innovative products for the non-invasive treatment of non-melanoma skin cancer and keloids,” said Benson Suen, Vice President of International Sales at Sensus Healthcare. “MIS Healthcare has an excellent reputation as a distributor of the highest quality medical devices, and brings a broad and growing network of relationships within the public and private healthcare sectors to support an effective market entry.”
“We are delighted to partner up with Sensus Healthcare and now distribute their superficial radiation therapy devices, which are giving patients new hope. With SRT, patients have a non-invasive, pain-free alternative for safely treating non-melanoma skin cancer and effectively removing keloids,” said Alex Britton, National Sales Manager-Oncology for MIS Healthcare.
About MIS Healthcare
With headquarters in London and offices in Wales and Scotland, MIS Healthcare is a diversified distributor of world-renowned radiology and oncology products. With more than 30 years of experience in the United Kingdom and Ireland public and private healthcare sectors, MIS strives to improve healthcare standards by partnering with world-class manufacturers and providing unrivalled sales and service support. The company has a large service and maintenance operation supported by a team of factory-trained engineers and applications specialists. MIS Healthcare strives to become the leader in its niche medical markets and to provide an unparalleled sales and service solution to its customers.
For more information, visit www.mishealthcare.co.uk.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100™, SRT-100+™ and SRT-100 Vision™ systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System™, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.
For more information, visit www.sensushealthcare.com.
Forward-Looking Statements
This press release includes statements that are, or may be deemed, ''forward-looking statements.'' In some cases, these statements can be identified by the use of forward-looking terminology such as "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," “approximately,” "potential" or negative or other variations of those terms or comparable terminology, although not all forward-looking statements contain these words.
Forward-looking statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to a greater or lesser degree than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward looking statements contained in this press release, as a result of the following factors, among others: our ability to return to profitability; our ability to sell the number of SRT units we anticipate for the balance of 2023; the possibility that inflationary pressures continue to impact our sales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing or otherwise violating the intellectual property rights of third parties; the level and availability of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular customer in the U.S.; and other risks described from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To date, we do not expect that the Russian invasion of Ukraine and global geopolitical uncertainty have not had any particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
In addition, even if future events, developments, and circumstances are consistent with the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods. Any forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable law. You should read carefully our "Introductory Note Regarding Forward-Looking Information" and the factors described in the "Risk Factors" section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
# # #
